#Liechtenstein #Vaduz #Implantica #RefluxStop #med-tech

Implantica's Annual Report 2024: Setting New Standards in Medical Technology

Implantica AG, a pioneering med-tech organization based in Liechtenstein, has recently unveiled its annual report for the fiscal year 2024. This comprehensive document is now accessible on the company's official website and showcases significant advancements in medical technology aimed at enhancing patient care.

One of the highlights of the report is the remarkable progress achieved with their primary product, RefluxStop™. This innovative gastroesophageal reflux implant has successfully transformed the lives of over 1,200 patients. The treatment was administered by 45 top-tier European anti-reflux surgeons from renowned medical centers across Germany, Switzerland, the UK, Italy, Spain, Austria, Norway, and Sweden. Moreover, there is an enthusiastic interest from over 100 U.S. surgeons who are eager to incorporate RefluxStop™ into their practices as soon as the product becomes available in the United States.

Dr. Peter Forsell, CEO of Implantica, expressed pride in these achievements, stating, “Today, we are proud to report that RefluxStop™ has achieved a crucial milestone in transforming the lives of now more than 1,200 patients... U.S. prelaunch activities are ongoing with detailed cost-benefit analyses, preparation of necessary documentation for U.S. payers, and the identification of 40 hospitals for the initial launch.”

Looking Ahead: U.S. Expansion and Partnerships

As part of its strategic plan for the U.S. market, Implantica is intently engaged in prelaunch efforts that include a thorough assessment of the costs and benefits associated with RefluxStop™. This critical analysis ensures that healthcare providers understand the value proposition of the product. Additionally, the company is preparing a robust dossier to meet U.S. payer requirements, ensuring that they can effectively position the device within the highly competitive U.S. healthcare landscape.

The establishment of partnerships with leading healthcare facilities will be pivotal as Implantica transitions to launching RefluxStop™ in the U.S. market. By collaborating with 40 carefully selected hospitals, the company aims to create an effective support system that will enable the device to be adopted seamlessly into clinical practices.

About Implantica’s Technology

Implantica strives to remain at the forefront of medical innovation through its commitment to developing advanced technological solutions. The company’s flagship product, RefluxStop™, is not only CE-marked but also represents a potential paradigm shift in anti-reflux treatments, backed by favorable clinical trial results.

Beyond RefluxStop™, Implantica is committed to exploring eHealth solutions that will further enhance patient care inside the body. Their product pipeline is protected by patents and includes two innovative platform technologies designed to monitor health parameters and control treatments from within the body, emphasizing the seamless communication between patients and caregivers.

Market Presence and Future Aspirations

Implantica is publicly traded on the Nasdaq First North Premier Growth Market under the ticker symbol IMP A SDB. The company’s continuous commitment to innovation in medical technology positions it as a leader in the industry. The annual report outlines not only the achievements of the past year but also their vision for the future—the potential expansion into the U.S. market, innovative applications of technology, and the promise of better patient care management for gastrointestinal conditions.

For more detailed information, the annual report is available on the Implantica website, where updates and insights into their technologies can also be found.

In conclusion, Implantica's annual report for 2024 marks a significant milestone in their journey toward revolutionizing medical technology, with RefluxStop™ leading the way in transforming patient experiences and outcomes.